Cangene Corp to fund Alzheimer's research

Cangene Corp has signed an MOU with the Univ of British Columbia to develop the research of Dr Neil Cashman, science director of PrioNet Canada and holder of the Canada Research Chair in neurodegeneration and protein misfolding at UBC. Winnipeg-based Cangene became interested in Cashman's work when a research team led by Cashman discovered a way to target amyloid beta oligomers responsible for the progression of Alzheimer's while sparing normal amyloid beta molecules. The early-stage discovery could form the basis of safe immunotherapy infusion, leading to a Canadian-made therapy for the disease. The agreement between Cangene and Cashman's PrioNet research team was facilitated by UBC's University-Industry Liaison Office....